WO2012109233A3 - Methods for predicting recurrence risk in breast cancer patients - Google Patents

Methods for predicting recurrence risk in breast cancer patients Download PDF

Info

Publication number
WO2012109233A3
WO2012109233A3 PCT/US2012/024133 US2012024133W WO2012109233A3 WO 2012109233 A3 WO2012109233 A3 WO 2012109233A3 US 2012024133 W US2012024133 W US 2012024133W WO 2012109233 A3 WO2012109233 A3 WO 2012109233A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
recurrence risk
breast cancer
cancer patients
predicting recurrence
Prior art date
Application number
PCT/US2012/024133
Other languages
French (fr)
Other versions
WO2012109233A2 (en
Inventor
Gordon B. Mills
Zhenlin JU
Kevin Coombes
Bryan HENNESSY
Original Assignee
Board Of Regents, The University Of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Board Of Regents, The University Of Texas System filed Critical Board Of Regents, The University Of Texas System
Publication of WO2012109233A2 publication Critical patent/WO2012109233A2/en
Publication of WO2012109233A3 publication Critical patent/WO2012109233A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Abstract

The invention relates to methods and kits useful for predicting or assessing recurrence risk in a patient having breast cancer who has been administered or treated with an anti-estrogen drug. Protein marker panels and methods of using the expression levels of these protein markers in calculating cancer recurrence risk and likelihood of response to the treatment are provided.
PCT/US2012/024133 2011-02-07 2012-02-07 Methods for predicting recurrence risk in breast cancer patients WO2012109233A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161440213P 2011-02-07 2011-02-07
US61/440,213 2011-02-07

Publications (2)

Publication Number Publication Date
WO2012109233A2 WO2012109233A2 (en) 2012-08-16
WO2012109233A3 true WO2012109233A3 (en) 2012-10-04

Family

ID=46639155

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/024133 WO2012109233A2 (en) 2011-02-07 2012-02-07 Methods for predicting recurrence risk in breast cancer patients

Country Status (1)

Country Link
WO (1) WO2012109233A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK177532B1 (en) 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
WO2011135459A2 (en) 2010-04-29 2011-11-03 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy
US10392667B2 (en) 2013-06-07 2019-08-27 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy of fulvestrant in cancer patients
WO2016046640A2 (en) 2014-09-26 2016-03-31 Medical Prognosis Institute A/S Methods for predicting drug responsiveness
US9725769B1 (en) 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
AU2017258901A1 (en) 2016-12-30 2018-07-19 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080108091A1 (en) * 2006-08-07 2008-05-08 Hennessy Bryan T Proteomic Patterns of Cancer Prognostic and Predictive Signatures
US7569345B2 (en) * 2003-01-15 2009-08-04 Genomic Health, Inc. Gene expression markers for breast cancer prognosis
US20100209920A1 (en) * 2002-03-13 2010-08-19 Baker Joffre B Gene Expression Profiling in Biopsied Tumor Tissues

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100209920A1 (en) * 2002-03-13 2010-08-19 Baker Joffre B Gene Expression Profiling in Biopsied Tumor Tissues
US7569345B2 (en) * 2003-01-15 2009-08-04 Genomic Health, Inc. Gene expression markers for breast cancer prognosis
US20080108091A1 (en) * 2006-08-07 2008-05-08 Hennessy Bryan T Proteomic Patterns of Cancer Prognostic and Predictive Signatures

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AHMAD ET AL.: "Stromelysin 3: an independent prognostic factor for relapse-free survival in node- positive breast cancer and demonstration of novel breast carcinoma cell expression", AM. J. PATHOL., vol. 152, no. 3, March 1998 (1998-03-01), pages 721 - 728 *
STANWAY ET AL.: "Steroid sulfatase: a new target for the endocrine therapy of breast cancer", ONCOLOGIST, vol. 12, no. 4, April 2007 (2007-04-01), pages 370 - 374 *

Also Published As

Publication number Publication date
WO2012109233A2 (en) 2012-08-16

Similar Documents

Publication Publication Date Title
PH12016501728A1 (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
EP3208615A3 (en) Uses of labeled hsp90 inhibitors
MX2021010672A (en) Diagnosis and therapy of cancer involving cancer stem cells.
MX366130B (en) Bivalent inhibitors of iap proteins and therapeutic methods using the same.
MX2014005800A (en) Human notch receptor mutations and their use.
MX353482B (en) METHODS FOR THE TREATMENT OF CANCER and INFLAMMATORY DISEASES USING CEREBLON AS A PREDICTOR.
BR112012020373A8 (en) isolated antibody, cell, isolated nucleic acid, method of identification, cell proliferation inhibition, therapeutic treatment, determination of the presence of a tat419 protein, diagnosis of the presence of cancer and distribution of cytotoxic agent
WO2012006589A3 (en) Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
MX2017014338A (en) Targeted selection of patients for treatment with cortistatin derivatives.
WO2012038068A8 (en) Means and methods for the prediction of treatment response of a cancer patient
MX2016001587A (en) Kdm1a inhibitors for the treatment of disease.
MX358517B (en) Methods for determining drug efficacy using cereblon-associated proteins.
WO2012109233A3 (en) Methods for predicting recurrence risk in breast cancer patients
WO2012177595A9 (en) Compositions and methods for the therapy and diagnosis of cancer
BR112013011480A2 (en) cancer treatment method, method of enhancing the therapeutic effectiveness of an anticancer drug, pmo1183 or a pharmaceutically acceptable salt thereof, use thereof and kit for use in cancer treatment
MX2013000675A (en) Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy.
WO2012061683A3 (en) Methods for treating cancer
BR112014027905A2 (en) antibody, cell, nucleic acid, methods of identifying a first antibody, inhibiting cell growth, therapeutic treatment, determining the presence of a protein, diagnosing a tumor, and delivering a cytotoxic agent.
WO2013083098A3 (en) Method of determination of cancer cell drug sensitivity towards aurora kinase inhibitors
WO2012145535A3 (en) Animal model of human cancer and methods of use
WO2012109466A3 (en) Long non-coding rna spry4-it1 as a diagnostic and therapeutic agent
SG11201400919RA (en) Patient stratification and determining clinical outcome for cancer patients
SG11202103913WA (en) Method for quantifying molecular activity in cancer cells of a human tumour
IL212800A0 (en) N-cadherin: target for cancer diagnosis and therapy
WO2011066082A3 (en) Markers associated with ribavirin-induced anemia

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12744652

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12744652

Country of ref document: EP

Kind code of ref document: A2